News
Market and company headlines
ALVOAll
Loading
04:00-06:00Oct 202 Stories
Alvotech shares jump premarket after FDA approves new Simlandi process
Investing.com -- Alvotech shares rose more than 6% in premarket trading Tuesday after the U.S. Food and Drug Administration approved a new manufacturing process for Simlandi, the company’s biosimilar to Humira.
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolioREYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-
19:00Oct 161 Story
04:00Oct 141 Story
07:00Oct 82 Stories
LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply
LOTTE Biologics, a contract development and manufacturing (CDMO) organization, and Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term strategic manufacturing partnership.
Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity Updates
Alvotech (NasdaqGM:ALVO) is back in focus after two closely timed manufacturing updates that reshape how its biosimilars could be supplied to major markets. Both moves revolve around capacity, regulatory readiness, and long term supply security. Recent trading shows that Alvotech has been back on investors’ radar, with a 30-day share price return of 9.96% and a 90-day move of 76.20% pointing to building momentum around the manufacturing updates, even though the 1-year total shareholder return...
12:00-17:00Oct 62 Stories
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Alvotech and LOTTE Biologics signing ceremony Alvotech and LOTTE Biologics signing ceremony to commemorate the formation of a strategic manufacturing agreement on October 6, 2026 Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (
Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term partnership to increase Alvotech’s global manufacturing capacity and support
11:00-16:00Oct 52 Stories
Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity
Key TakeawaysAlvotech shares rose 13% after the FDA approved a second Reykjavik production suite for Simlandi, its Humira biosimilar, doubling the capacity available for U. S.
Alvotech stock surges after FDA manufacturing approval
Investing.com -- Alvotech SA (NASDAQ:ALVO) shares jumped 13.5% Monday after the U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02, enabling the company to manufacture the drug substance in a second production suite at its Reykjavik facility.
04:00Oct 51 Story
06:00-11:00Sep 162 Stories
Gapping stocks in Wednesday's session
Let's have a look at the gap up and gap down stocks in today's session.
Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target
Alvotech (NASDAQ:ALVO) shares gained 5. 6% in premarket trading after Barclays upgraded the biosimilar drug developer from Underweight to Overweight and raised its price target from $4.
04:00-06:00Sep 162 Stories
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8
Barclays analyst Glen Santangelo upgrades Alvotech (NASDAQ:ALVO) from Underweight to Overweight and raises the price target from $4 to $8.
11:00Sep 151 Story
09:00-20:00Aug 242 Stories
Alvotech (ALVO) Gets New ‘Buy’ Reco. Should Investors Follow?
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares increased by
06:00-09:00Aug 243 Stories
Crude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.
BofA starts bullish Alvotech coverage on biosimilar launch cycle
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.
03:00Aug 241 Story
11:00Aug 211 Story
05:00-08:00Aug 202 Stories
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
Alvotech (ALVO) Q2 2026 Earnings Call August 20, 2026 8:00 AM EDTCompany ParticipantsBenedikt Stefansson - Vice President of Investor Relations & Global...
Alvotech Q2 2026 Earnings Call Transcript
Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
12:00Aug 192 Stories
Alvotech Q2 EPS $(0.17) Misses $(0.04) Estimate, Sales $106.000M Miss $111.010M Estimate
Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.04) by 325 percent. This is a 221.43 percent decrease over earnings of $0.14 per share from the
Alvotech Affirms FY2026 Sales Guidance of $650.000M-$700.000M vs $644.838M Est
Alvotech (NASDAQ:ALVO) affirms FY2026 sales outlook from $650.000 million-$700.000 million to $650.000 million-$700.000 million vs $644.838 million estimate.
